Yoshikawa, Takaki
Kikko, Yorifumi
Makino, Reina
Kimijima, Yuya
Nishiyama, Eiji
Matsuda, Yuko
Casaes Teixeira, Bruno
Tejada, Mariella
Carroll, Robert
Hironaka, Shuichi http://orcid.org/0000-0001-9714-231X
Funding for this research was provided by:
Bristol Myers Squibb
Article History
Received: 6 December 2023
Accepted: 3 April 2024
First Online: 30 April 2024
Change Date: 15 July 2024
Change Type: Update
Change Details: Grammatical errors in the article title and article note were corrected.
Declarations
:
: Dr. Takaki Yoshikawa has received lecture fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd, Medtronic Japan Co., Ltd., Bristol-Myers Squibb K.K., EA Pharma Co., Ltd., Johnson & Johnson K.K., AstraZeneca K.K., Intuitive Surgical, Inc., Japan Blood Products Organization, Olympus, Eli Lilly Japan K.K., and Astellas Pharma Inc. Yorifumi Kikko has received medical writing/editorial support from Bristol-Myers Squibb K.K., and Ono Pharmaceutical Co., Ltd.; and is an employee of Bristol-Myers Squibb K.K. Reina Makino is an employee of Ono Pharmaceutical Co., Ltd. Yuya Kimijima is an employee of Bristol-Myers Squibb K.K. Eiji Nishiyama and Yuko Matsuda are employees of Ono Pharmaceutical Co., Ltd. Bruno Casaes Teixeira is an employee of and holds stock or stock options in Bristol Myers Squibb. Mariella Tejada is an employee of Bristol Myers Squibb. Robert Carroll is an employee of Bristol Myers Squibb. Dr. Shuichi Hironaka has received consulting fees from Astellas; and has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Taiho Pharmaceutical Co., Ltd., Sanofi K.K., AstraZeneca K.K., Yakult Honsha Co., Ltd., and Bayer Pharma.
: All procedures followed were in accordance with the principles of the Helsinki Declaration of 1964 and later versions, the International Society for Pharmacoepidemiology Guidelines for Good Pharmacoepidemiology Practices and regulations associated with scientific and medical research involving human subjects in Japan. Ethics committee review and approval prior to study initiation were not required because the MDV database had undergone extensive ethical review and approval in relation to contracts with individual hospital data providers. Because data elements in the MDV database have been de-identified, informed consent was not required.